BG61967B1 - Метод и средство за профилактика и лечение на заболявания,причинени от ендотоксини - Google Patents

Метод и средство за профилактика и лечение на заболявания,причинени от ендотоксини Download PDF

Info

Publication number: BG61967B1
Authority: BG; Bulgaria
Prior art keywords: pharmaceutical agent; agent according; phospholipid; neutral lipid; weight
Prior art date: 1994-08-10

Application number

BG101288A

Other languages

Bulgarian (bg)

English (en)

Other versions

BG101288A (en

Inventor

Daniel M. Levine

Thomas S. Parker

Albert L. Rubin

Bruce R. Gordon

Stuart D. Saal

Original Assignee

Rogosin Insitute

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1994-08-10

Filing date

1997-03-05

Publication date

1998-11-30

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26965092&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BG61967(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

1994-08-10 Priority claimed from US08/288,568 external-priority patent/US5506218A/en

1997-03-05 Application filed by Rogosin Insitute filed Critical Rogosin Insitute

1997-09-30 Publication of BG101288A publication Critical patent/BG101288A/xx

1998-11-30 Publication of BG61967B1 publication Critical patent/BG61967B1/bg

Links

238000000034 method Methods 0.000 title claims abstract description 9
238000011282 treatment Methods 0.000 title claims description 11
201000010099 disease Diseases 0.000 title claims 4
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title claims 4
238000002360 preparation method Methods 0.000 title description 25
150000003904 phospholipids Chemical class 0.000 claims abstract description 63
150000002632 lipids Chemical class 0.000 claims abstract description 60
230000007935 neutral effect Effects 0.000 claims abstract description 44
108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 15
102000004169 proteins and genes Human genes 0.000 claims abstract description 13
108090000623 proteins and genes Proteins 0.000 claims abstract description 13
150000003839 salts Chemical class 0.000 claims abstract description 13
239000002253 acid Substances 0.000 claims abstract description 12
102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 8
WTJKGGKOPKCXLL-RRHRGVEJSA-N phosphatidylcholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCCCCCCC=CCCCCCCCC WTJKGGKOPKCXLL-RRHRGVEJSA-N 0.000 claims description 45
239000002158 endotoxin Substances 0.000 claims description 42
UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 claims description 28
HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 claims description 27
239000003613 bile acid Substances 0.000 claims description 19
150000001840 cholesterol esters Chemical class 0.000 claims description 18
BHQCQFFYRZLCQQ-OELDTZBJSA-N cholic acid Chemical compound C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-OELDTZBJSA-N 0.000 claims description 16
208000037487 Endotoxemia Diseases 0.000 claims description 15
239000000203 mixture Substances 0.000 claims description 14
241001465754 Metazoa Species 0.000 claims description 12
230000037396 body weight Effects 0.000 claims description 12
235000019416 cholic acid Nutrition 0.000 claims description 10
KXGVEGMKQFWNSR-UHFFFAOYSA-N deoxycholic acid Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 KXGVEGMKQFWNSR-UHFFFAOYSA-N 0.000 claims description 10
NRHMKIHPTBHXPF-TUJRSCDTSA-M sodium cholate Chemical group [Na+].C([C@H]1C[C@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 NRHMKIHPTBHXPF-TUJRSCDTSA-M 0.000 claims description 10
BHQCQFFYRZLCQQ-UHFFFAOYSA-N (3alpha,5alpha,7alpha,12alpha)-3,7,12-trihydroxy-cholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)C(O)C2 BHQCQFFYRZLCQQ-UHFFFAOYSA-N 0.000 claims description 9
239000004380 Cholic acid Substances 0.000 claims description 9
229960002471 cholic acid Drugs 0.000 claims description 9
229960001231 choline Drugs 0.000 claims description 7
OEYIOHPDSNJKLS-UHFFFAOYSA-N choline Chemical compound C[N+](C)(C)CCO OEYIOHPDSNJKLS-UHFFFAOYSA-N 0.000 claims description 7
230000002265 prevention Effects 0.000 claims description 7
229960003964 deoxycholic acid Drugs 0.000 claims description 4
150000003408 sphingolipids Chemical class 0.000 claims description 4
DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
238000004519 manufacturing process Methods 0.000 claims description 3
229910052708 sodium Inorganic materials 0.000 claims description 3
239000011734 sodium Substances 0.000 claims description 3
229940083542 sodium Drugs 0.000 claims description 3
239000003814 drug Substances 0.000 claims description 2
238000011321 prophylaxis Methods 0.000 claims description 2
239000008177 pharmaceutical agent Substances 0.000 claims 27
RPKLZQLYODPWTM-KBMWBBLPSA-N cholanoic acid Chemical compound C1CC2CCCC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@@H](CCC(O)=O)C)[C@@]1(C)CC2 RPKLZQLYODPWTM-KBMWBBLPSA-N 0.000 claims 2
WWUZIQQURGPMPG-UHFFFAOYSA-N (-)-D-erythro-Sphingosine Natural products CCCCCCCCCCCCCC=CC(O)C(N)CO WWUZIQQURGPMPG-UHFFFAOYSA-N 0.000 claims 1
241000208202 Linaceae Species 0.000 claims 1
235000004431 Linum usitatissimum Nutrition 0.000 claims 1
FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 claims 1
WWUZIQQURGPMPG-KRWOKUGFSA-N sphingosine Chemical compound CCCCCCCCCCCCC\C=C\[C@@H](O)[C@@H](N)CO WWUZIQQURGPMPG-KRWOKUGFSA-N 0.000 claims 1
238000002560 therapeutic procedure Methods 0.000 claims 1
150000003626 triacylglycerols Chemical class 0.000 abstract description 8
150000007513 acids Chemical class 0.000 abstract description 3
210000000941 bile Anatomy 0.000 abstract 1
239000000839 emulsion Substances 0.000 description 52
HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 22
229920006008 lipopolysaccharide Polymers 0.000 description 22
239000003795 chemical substances by application Substances 0.000 description 18
230000004083 survival effect Effects 0.000 description 12
235000012000 cholesterol Nutrition 0.000 description 11
102000015779 HDL Lipoproteins Human genes 0.000 description 10
108010010234 HDL Lipoproteins Proteins 0.000 description 10
108060008682 Tumor Necrosis Factor Proteins 0.000 description 10
238000002474 experimental method Methods 0.000 description 10
239000000126 substance Substances 0.000 description 10
239000008280 blood Substances 0.000 description 9
210000004369 blood Anatomy 0.000 description 9
239000002245 particle Substances 0.000 description 9
241000588724 Escherichia coli Species 0.000 description 8
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 8
238000012360 testing method Methods 0.000 description 8
102000007592 Apolipoproteins Human genes 0.000 description 7
108010071619 Apolipoproteins Proteins 0.000 description 7
102000004895 Lipoproteins Human genes 0.000 description 7
108090001030 Lipoproteins Proteins 0.000 description 7
208000005374 Poisoning Diseases 0.000 description 7
239000008121 dextrose Substances 0.000 description 7
231100000572 poisoning Toxicity 0.000 description 7
230000000607 poisoning effect Effects 0.000 description 7
MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 6
GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 6
102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 6
229940099352 cholate Drugs 0.000 description 6
238000001990 intravenous administration Methods 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 5
239000003833 bile salt Substances 0.000 description 5
229940028435 intralipid Drugs 0.000 description 5
230000001681 protective effect Effects 0.000 description 5
239000000243 solution Substances 0.000 description 5
-1 sphingolipids Chemical class 0.000 description 5
231100000419 toxicity Toxicity 0.000 description 5
230000001988 toxicity Effects 0.000 description 5
241000894006 Bacteria Species 0.000 description 4
241000283973 Oryctolagus cuniculus Species 0.000 description 4
BAECOWNUKCLBPZ-HIUWNOOHSA-N Triolein Natural products O([C@H](OCC(=O)CCCCCCC/C=C\CCCCCCCC)COC(=O)CCCCCCC/C=C\CCCCCCCC)C(=O)CCCCCCC/C=C\CCCCCCCC BAECOWNUKCLBPZ-HIUWNOOHSA-N 0.000 description 4
PHYFQTYBJUILEZ-UHFFFAOYSA-N Trioleoylglycerol Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(OC(=O)CCCCCCCC=CCCCCCCCC)COC(=O)CCCCCCCC=CCCCCCCCC PHYFQTYBJUILEZ-UHFFFAOYSA-N 0.000 description 4
239000003963 antioxidant agent Substances 0.000 description 4
235000006708 antioxidants Nutrition 0.000 description 4
238000009534 blood test Methods 0.000 description 4
230000000694 effects Effects 0.000 description 4
238000001727 in vivo Methods 0.000 description 4
239000011780 sodium chloride Substances 0.000 description 4
PHYFQTYBJUILEZ-IUPFWZBJSA-N triolein Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC(OC(=O)CCCCCCC\C=C/CCCCCCCC)COC(=O)CCCCCCC\C=C/CCCCCCCC PHYFQTYBJUILEZ-IUPFWZBJSA-N 0.000 description 4
229940117972 triolein Drugs 0.000 description 4
102000003390 tumor necrosis factor Human genes 0.000 description 4
235000019165 vitamin E Nutrition 0.000 description 4
239000011709 vitamin E Substances 0.000 description 4
YYGNTYWPHWGJRM-UHFFFAOYSA-N (6E,10E,14E,18E)-2,6,10,15,19,23-hexamethyltetracosa-2,6,10,14,18,22-hexaene Chemical compound CC(C)=CCCC(C)=CCCC(C)=CCCC=C(C)CCC=C(C)CCC=C(C)C YYGNTYWPHWGJRM-UHFFFAOYSA-N 0.000 description 3
239000004215 Carbon black (E152) Substances 0.000 description 3
235000010469 Glycine max Nutrition 0.000 description 3
BHEOSNUKNHRBNM-UHFFFAOYSA-N Tetramethylsqualene Natural products CC(=C)C(C)CCC(=C)C(C)CCC(C)=CCCC=C(C)CCC(C)C(=C)CCC(C)C(C)=C BHEOSNUKNHRBNM-UHFFFAOYSA-N 0.000 description 3
229930003427 Vitamin E Natural products 0.000 description 3
229940093761 bile salts Drugs 0.000 description 3
KXGVEGMKQFWNSR-LLQZFEROSA-N deoxycholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-LLQZFEROSA-N 0.000 description 3
PRAKJMSDJKAYCZ-UHFFFAOYSA-N dodecahydrosqualene Natural products CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 3
238000009472 formulation Methods 0.000 description 3
WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 3
229930195733 hydrocarbon Natural products 0.000 description 3
150000002430 hydrocarbons Chemical class 0.000 description 3
GZQKNULLWNGMCW-PWQABINMSA-N lipid A (E. coli) Chemical compound O1[C@H](CO)[C@@H](OP(O)(O)=O)[C@H](OC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCCCC)[C@@H](NC(=O)C[C@@H](CCCCCCCCCCC)OC(=O)CCCCCCCCCCC)[C@@H]1OC[C@@H]1[C@@H](O)[C@H](OC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](NC(=O)C[C@H](O)CCCCCCCCCCC)[C@@H](OP(O)(O)=O)O1 GZQKNULLWNGMCW-PWQABINMSA-N 0.000 description 3
239000007788 liquid Substances 0.000 description 3
238000010172 mouse model Methods 0.000 description 3
229940031439 squalene Drugs 0.000 description 3
TUHBEKDERLKLEC-UHFFFAOYSA-N squalene Natural products CC(=CCCC(=CCCC(=CCCC=C(/C)CCC=C(/C)CC=C(C)C)C)C)C TUHBEKDERLKLEC-UHFFFAOYSA-N 0.000 description 3
230000006433 tumor necrosis factor production Effects 0.000 description 3
229940046009 vitamin E Drugs 0.000 description 3
XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 2
IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
206010014824 Endotoxic shock Diseases 0.000 description 2
DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
244000068988 Glycine max Species 0.000 description 2
239000012981 Hank's balanced salt solution Substances 0.000 description 2
241000699666 Mus <mouse, genus> Species 0.000 description 2
206010040070 Septic Shock Diseases 0.000 description 2
239000004480 active ingredient Substances 0.000 description 2
230000003078 antioxidant effect Effects 0.000 description 2
229940078967 bile acid preparations for bile therapy Drugs 0.000 description 2
230000001419 dependent effect Effects 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000011534 incubation Methods 0.000 description 2
238000001802 infusion Methods 0.000 description 2
231100000636 lethal dose Toxicity 0.000 description 2
239000002960 lipid emulsion Substances 0.000 description 2
239000012528 membrane Substances 0.000 description 2
238000002156 mixing Methods 0.000 description 2
238000006386 neutralization reaction Methods 0.000 description 2
239000003921 oil Substances 0.000 description 2
230000036470 plasma concentration Effects 0.000 description 2
239000007787 solid Substances 0.000 description 2
238000001356 surgical procedure Methods 0.000 description 2
XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
235000021476 total parenteral nutrition Nutrition 0.000 description 2
231100000331 toxic Toxicity 0.000 description 2
230000002588 toxic effect Effects 0.000 description 2
210000003462 vein Anatomy 0.000 description 2
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
238000005303 weighing Methods 0.000 description 2
RUDATBOHQWOJDD-UHFFFAOYSA-N (3beta,5beta,7alpha)-3,7-Dihydroxycholan-24-oic acid Natural products OC1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 RUDATBOHQWOJDD-UHFFFAOYSA-N 0.000 description 1
LDVVTQMJQSCDMK-UHFFFAOYSA-N 1,3-dihydroxypropan-2-yl formate Chemical compound OCC(CO)OC=O LDVVTQMJQSCDMK-UHFFFAOYSA-N 0.000 description 1
JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 1
102000004506 Blood Proteins Human genes 0.000 description 1
108010017384 Blood Proteins Proteins 0.000 description 1
238000011740 C57BL/6 mouse Methods 0.000 description 1
238000002965 ELISA Methods 0.000 description 1
102000002322 Egg Proteins Human genes 0.000 description 1
108010000912 Egg Proteins Proteins 0.000 description 1
239000004471 Glycine Substances 0.000 description 1
239000007995 HEPES buffer Substances 0.000 description 1
101001120470 Haemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd) Peptidoglycan-associated lipoprotein Proteins 0.000 description 1
206010024626 Lipoprotein deficiency Diseases 0.000 description 1
SMEROWZSTRWXGI-UHFFFAOYSA-N Lithocholsaeure Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(CCC(O)=O)C)C1(C)CC2 SMEROWZSTRWXGI-UHFFFAOYSA-N 0.000 description 1
241000607142 Salmonella Species 0.000 description 1
229930182558 Sterol Natural products 0.000 description 1
239000013543 active substance Substances 0.000 description 1
125000002252 acyl group Chemical group 0.000 description 1
239000002671 adjuvant Substances 0.000 description 1
KXGVEGMKQFWNSR-WFTUMUMQSA-N allodeoxycholic acid Chemical compound C([C@@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 KXGVEGMKQFWNSR-WFTUMUMQSA-N 0.000 description 1
229910052786 argon Inorganic materials 0.000 description 1
230000001580 bacterial effect Effects 0.000 description 1
OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 description 1
229940076810 beta sitosterol Drugs 0.000 description 1
LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 description 1
NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 description 1
230000031018 biological processes and functions Effects 0.000 description 1
238000007664 blowing Methods 0.000 description 1
230000001413 cellular effect Effects 0.000 description 1
238000005119 centrifugation Methods 0.000 description 1
239000003153 chemical reaction reagent Substances 0.000 description 1
239000002812 cholic acid derivative Substances 0.000 description 1
150000001842 cholic acids Chemical class 0.000 description 1
238000005352 clarification Methods 0.000 description 1
238000004590 computer program Methods 0.000 description 1
239000000470 constituent Substances 0.000 description 1
230000007423 decrease Effects 0.000 description 1
238000011161 development Methods 0.000 description 1
239000006185 dispersion Substances 0.000 description 1
235000013345 egg yolk Nutrition 0.000 description 1
210000002969 egg yolk Anatomy 0.000 description 1
235000013601 eggs Nutrition 0.000 description 1
230000001804 emulsifying effect Effects 0.000 description 1
231100000284 endotoxic Toxicity 0.000 description 1
230000002346 endotoxic effect Effects 0.000 description 1
150000002148 esters Chemical class 0.000 description 1
239000000706 filtrate Substances 0.000 description 1
239000007789 gas Substances 0.000 description 1
MSWZFWKMSRAUBD-IVMDWMLBSA-N glucosamine group Chemical group OC1[C@H](N)[C@@H](O)[C@H](O)[C@H](O1)CO MSWZFWKMSRAUBD-IVMDWMLBSA-N 0.000 description 1
150000004676 glycans Polymers 0.000 description 1
239000008187 granular material Substances 0.000 description 1
208000015181 infectious disease Diseases 0.000 description 1
239000004615 ingredient Substances 0.000 description 1
230000005764 inhibitory process Effects 0.000 description 1
230000003993 interaction Effects 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000011031 large-scale manufacturing process Methods 0.000 description 1
231100000518 lethal Toxicity 0.000 description 1
230000001665 lethal effect Effects 0.000 description 1
231100000225 lethality Toxicity 0.000 description 1
SMEROWZSTRWXGI-HVATVPOCSA-N lithocholic acid Chemical compound C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 SMEROWZSTRWXGI-HVATVPOCSA-N 0.000 description 1
239000000463 material Substances 0.000 description 1
230000001404 mediated effect Effects 0.000 description 1
230000000116 mitigating effect Effects 0.000 description 1
230000003472 neutralizing effect Effects 0.000 description 1
229910052757 nitrogen Inorganic materials 0.000 description 1
238000011017 operating method Methods 0.000 description 1
150000008105 phosphatidylcholines Chemical class 0.000 description 1
150000004804 polysaccharides Polymers 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
230000008569 process Effects 0.000 description 1
230000001698 pyrogenic effect Effects 0.000 description 1
238000011555 rabbit model Methods 0.000 description 1
239000002994 raw material Substances 0.000 description 1
210000002966 serum Anatomy 0.000 description 1
KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 description 1
229950005143 sitosterol Drugs 0.000 description 1
241000894007 species Species 0.000 description 1
238000007619 statistical method Methods 0.000 description 1
150000003432 sterols Chemical class 0.000 description 1
235000003702 sterols Nutrition 0.000 description 1
230000000638 stimulation Effects 0.000 description 1
238000003756 stirring Methods 0.000 description 1
230000001629 suppression Effects 0.000 description 1
230000002459 sustained effect Effects 0.000 description 1
229960003080 taurine Drugs 0.000 description 1
229940124597 therapeutic agent Drugs 0.000 description 1
230000001960 triggered effect Effects 0.000 description 1
BHQCQFFYRZLCQQ-UTLSPDKDSA-N ursocholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)[C@@H](O)C1 BHQCQFFYRZLCQQ-UTLSPDKDSA-N 0.000 description 1
RUDATBOHQWOJDD-UZVSRGJWSA-N ursodeoxycholic acid Chemical compound C([C@H]1C[C@@H]2O)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC(O)=O)C)[C@@]2(C)CC1 RUDATBOHQWOJDD-UZVSRGJWSA-N 0.000 description 1
229960001661 ursodiol Drugs 0.000 description 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
- A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
- A61K9/1275—Lipoproteins or protein-free species thereof, e.g. chylomicrons; Artificial high-density lipoproteins [HDL], low-density lipoproteins [LDL] or very-low-density lipoproteins [VLDL]; Precursors thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/775—Apolipopeptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Epidemiology (AREA)
Bioinformatics & Cheminformatics (AREA)
Toxicology (AREA)
Engineering & Computer Science (AREA)
Gastroenterology & Hepatology (AREA)
Biochemistry (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Communicable Diseases (AREA)
Dispersion Chemistry (AREA)
Zoology (AREA)
Oncology (AREA)
Molecular Biology (AREA)
Biophysics (AREA)
Genetics & Genomics (AREA)
Hematology (AREA)
Diabetes (AREA)
Medicinal Preparation (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

BG101288A 1994-08-10 1997-03-05 Метод и средство за профилактика и лечение на заболявания,причинени от ендотоксини BG61967B1 (bg)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US08/288,568 US5506218A (en)	1992-08-12	1994-08-10	Methods useful in endotoxin based therapy
US08/487,459 US5674855A (en)	1992-08-12	1995-06-07	Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions
PCT/US1995/010189 WO1996004916A1 (en)	1994-08-10	1995-08-10	Methods and compositions useful in prophylaxis and therapy of endotoxin related conditions

Publications (2)

Publication Number	Publication Date
BG101288A BG101288A (en)	1997-09-30
BG61967B1 true BG61967B1 (bg)	1998-11-30

Family

ID=26965092

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BG101288A BG61967B1 (bg)	1994-08-10	1997-03-05	Метод и средство за профилактика и лечение на заболявания,причинени от ендотоксини

Country Status (27)

Country	Link
US (1)	US5674855A (sv)
EP (1)	EP0767666B1 (sv)
JP (1)	JP3818660B2 (sv)
CN (1)	CN1137688C (sv)
AP (1)	AP782A (sv)
AT (1)	ATE255415T1 (sv)
AU (1)	AU703861C (sv)
BG (1)	BG61967B1 (sv)
BR (1)	BR9508584A (sv)
CA (1)	CA2196906C (sv)
CY (1)	CY2514B1 (sv)
CZ (1)	CZ287614B6 (sv)
DE (1)	DE69532239T2 (sv)
DK (1)	DK0767666T3 (sv)
ES (1)	ES2211915T3 (sv)
FI (1)	FI118035B (sv)
HK (1)	HK1003709A1 (sv)
HU (1)	HUT77605A (sv)
NO (1)	NO313786B1 (sv)
NZ (1)	NZ292315A (sv)
OA (2)	OA11737A (sv)
PL (1)	PL182043B1 (sv)
PT (1)	PT767666E (sv)
RO (1)	RO115782B1 (sv)
RU (1)	RU2174839C2 (sv)
SK (1)	SK282493B6 (sv)
WO (1)	WO1996004916A1 (sv)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6518412B1 (en)	1997-09-29	2003-02-11	Jean-Louis Dasseux	Gene therapy approaches to supply apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6046166A (en)	1997-09-29	2000-04-04	Jean-Louis Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6037323A (en)	1997-09-29	2000-03-14	Jean-Louis Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
US6004925A (en)	1997-09-29	1999-12-21	J. L. Dasseux	Apolipoprotein A-I agonists and their use to treat dyslipidemic disorders
AU3809900A (en) *	1999-03-09	2000-09-28	Max-Delbruck-Centrum Fur Molekulare Medizin	Therapy and use of compounds in therapy
US20030032674A1 (en) *	2001-08-13	2003-02-13	Hwang Daniel H.	Use of unsaturated fatty acids to treat severe inflammatory diseases
BR0310099A (pt)	2002-05-17	2007-03-20	Esperion Therapeutics Inc	método para tratar dislipidemia ou uma doença associada com a dislipidemia
WO2004068969A1 (en) *	2003-02-05	2004-08-19	N.V. Nutricia	Enteral composition for the prevention and/or treatment of sepsis
HUE038247T2 (hu) *	2004-05-19	2018-10-29	Los Angeles Biomedical Res Inst Harbor Ucla Medical Ct	Nátrium-deoxikolátot tartalmazó injektálható készítmény
US7754230B2 (en) *	2004-05-19	2010-07-13	The Regents Of The University Of California	Methods and related compositions for reduction of fat
US20060127468A1 (en) *	2004-05-19	2006-06-15	Kolodney Michael S	Methods and related compositions for reduction of fat and skin tightening
NZ565590A (en) *	2005-08-29	2010-07-30	Sepsicure L L C	Use of a protein free composition comprising cholinic acid and a phosphosphlipid for the treatment or prevention of conditions caused by gram-positive bacteria
GB0522942D0 (en)	2005-11-10	2005-12-21	Leigh Steven	Dissolution composition
EP2537526A1 (en)	2006-06-01	2012-12-26	Institut de Cardiologie de Montréal	Method and compound for the treatment of valvular stenosis
KR100785656B1 (ko) *	2007-05-14	2007-12-17	재단법인서울대학교산학협력재단	소염제로 사용되는 소디움글리코콜레이트 또는 그 유도체
PL2396017T3 (pl)	2009-02-16	2015-12-31	Cerenis Therapeutics Holding Sa	Mimetyki apolipoproteiny A-l
US8101593B2 (en)	2009-03-03	2012-01-24	Kythera Biopharmaceuticals, Inc.	Formulations of deoxycholic acid and salts thereof
EP2675460A4 (en)	2011-02-18	2014-07-09	Kythera Biopharmaceuticals Inc	TREATMENT OF FAT TISSUE UNDER CHIN
US8653058B2 (en)	2011-04-05	2014-02-18	Kythera Biopharmaceuticals, Inc.	Compositions comprising deoxycholic acid and salts thereof suitable for use in treating fat deposits
US9023833B2 (en) *	2012-12-18	2015-05-05	Sepsicure, LLC	Method for treating sepsis in patients with albumin, cholesterol and HDL levels above minimum thresholds

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4115313A (en) *	1974-10-08	1978-09-19	Irving Lyon	Bile acid emulsions
DE2556592C2 (de) *	1975-12-16	1986-10-09	A. Nattermann & Cie GmbH, 5000 Köln	Arzneimittelzubereitungen auf Basis öliger Lösungen von Phospholipiden
US4314997A (en) *	1980-10-06	1982-02-09	Edward Shanbrom	Purification of plasma protein products
IL63734A (en) *	1981-09-04	1985-07-31	Yeda Res & Dev	Lipid fraction,its preparation and pharmaceutical compositions containing same
CA1237671A (en) *	1983-08-01	1988-06-07	Michael W. Fountain	Enhancement of pharmaceutical activity
JPS6193111A (ja) *	1984-05-28	1986-05-12	Funayama Seizo	発熱性物質除去方法
US5032585A (en) *	1987-02-17	1991-07-16	Board Of Regents, The University Of Texas System	Methods and compositions employing unique mixtures of polar and neutral lipids for surfactant replacement therapy
CA2013755C (en) *	1989-04-05	1993-11-30	Simon Benita	Medicinal emulsions
DE4017979A1 (de) *	1990-06-05	1991-12-12	Meyer Lucas Gmbh & Co	Lipid- bzw. phospholipid-zusammensetzungen sowie diese enthaltendes mittel zur behandlung von erkrankungen sowie auf die zellmembrane zurueckzufuehrende stoerungen
BR9201168A (pt) *	1992-04-02	1994-04-12	Zerbini E J Fundacao	Microemulsoes usadas como velculo para carregar quimioterapicos as celulas neoplasicas

1995
- 1995-06-07 US US08/487,459 patent/US5674855A/en not_active Expired - Lifetime
- 1995-08-10 SK SK176-97A patent/SK282493B6/sk not_active IP Right Cessation
- 1995-08-10 RU RU97104061/14A patent/RU2174839C2/ru active
- 1995-08-10 JP JP50750296A patent/JP3818660B2/ja not_active Expired - Fee Related
- 1995-08-10 ES ES95930812T patent/ES2211915T3/es not_active Expired - Lifetime
- 1995-08-10 WO PCT/US1995/010189 patent/WO1996004916A1/en active IP Right Grant
- 1995-08-10 AU AU34052/95A patent/AU703861C/en not_active Expired
- 1995-08-10 DK DK95930812T patent/DK0767666T3/da active
- 1995-08-10 CZ CZ1997371A patent/CZ287614B6/cs not_active IP Right Cessation
- 1995-08-10 PT PT95930812T patent/PT767666E/pt unknown
- 1995-08-10 NZ NZ292315A patent/NZ292315A/en not_active IP Right Cessation
- 1995-08-10 AP APAP/P/1997/000921A patent/AP782A/en active
- 1995-08-10 DE DE69532239T patent/DE69532239T2/de not_active Expired - Lifetime
- 1995-08-10 EP EP95930812A patent/EP0767666B1/en not_active Expired - Lifetime
- 1995-08-10 OA OA00100167A patent/OA11737A/en unknown
- 1995-08-10 CA CA002196906A patent/CA2196906C/en not_active Expired - Lifetime
- 1995-08-10 HU HU9700406A patent/HUT77605A/hu unknown
- 1995-08-10 RO RO97-00266A patent/RO115782B1/ro unknown
- 1995-08-10 CN CNB951951734A patent/CN1137688C/zh not_active Expired - Lifetime
- 1995-08-10 BR BR9508584A patent/BR9508584A/pt not_active IP Right Cessation
- 1995-08-10 PL PL95318593A patent/PL182043B1/pl unknown
- 1995-08-10 AT AT95930812T patent/ATE255415T1/de active
1997
- 1997-02-07 FI FI970534A patent/FI118035B/sv not_active IP Right Cessation
- 1997-02-07 NO NO19970582A patent/NO313786B1/no not_active IP Right Cessation
- 1997-02-07 OA OA60963A patent/OA10598A/en unknown
- 1997-03-05 BG BG101288A patent/BG61967B1/bg unknown
1998
- 1998-04-08 HK HK98102936A patent/HK1003709A1/xx not_active IP Right Cessation
2005
- 2005-06-03 CY CY0500036A patent/CY2514B1/xx unknown

Also Published As

Publication number	Publication date
AP782A (en)	1999-11-15
ES2211915T3 (es)	2004-07-16
RU2174839C2 (ru)	2001-10-20
AU3405295A (en)	1996-03-07
CA2196906C (en)	2004-03-02
RO115782B1 (ro)	2000-06-30
CZ287614B6 (en)	2001-01-17
HUT77605A (hu)	1998-06-29
AU703861C (en)	2001-12-20
NO970582L (no)	1997-04-07
DK0767666T3 (da)	2004-04-05
EP0767666B1 (en)	2003-12-03
PT767666E (pt)	2004-04-30
HK1003709A1 (en)	1998-11-06
FI118035B (sv)	2007-06-15
NZ292315A (en)	1998-10-28
EP0767666A1 (en)	1997-04-16
JP3818660B2 (ja)	2006-09-06
BR9508584A (pt)	1997-10-21
SK282493B6 (sk)	2002-02-05
FI970534L (sv)	1997-02-07
CN1158087A (zh)	1997-08-27
CA2196906A1 (en)	1996-02-22
SK17697A3 (en)	1997-09-10
PL318593A1 (en)	1997-06-23
FI970534A0 (sv)	1997-02-07
CY2514B1 (en)	2005-12-23
AU703861B2 (en)	1999-04-01
OA10598A (en)	2002-07-15
NO313786B1 (no)	2002-12-02
NO970582D0 (no)	1997-02-07
WO1996004916A1 (en)	1996-02-22
CZ37197A3 (en)	1997-10-15
DE69532239T2 (de)	2004-10-21
CN1137688C (zh)	2004-02-11
OA11737A (en)	2005-05-12
US5674855A (en)	1997-10-07
PL182043B1 (pl)	2001-10-31
DE69532239D1 (de)	2004-01-15
BG101288A (en)	1997-09-30
AP9700921A0 (en)	1997-01-31
EP0767666A4 (en)	1998-10-07
ATE255415T1 (de)	2003-12-15
JPH10504037A (ja)	1998-04-14

Publication	Publication Date	Title
BG61967B1 (bg)	1998-11-30	Метод и средство за профилактика и лечение на заболявания,причинени от ендотоксини
US5506218A (en)	1996-04-09	Methods useful in endotoxin based therapy
KR101413361B1 (ko)	2014-06-27	그람-양성 박테리아에 의해 유발되는 질병의 치료 또는예방 방법
US5587366A (en)	1996-12-24	Compositions useful in prophylaxis and therapy of endotoxin related conditions
KR100372672B1 (ko)	2003-06-19	엔도톡신관련질환의예방및치료에유용한조성물및방법
DE3412793A1 (de)	1985-10-17	Liposomen mit inhalativen allergenen zur behandlung von allergien, verfahren zu ihrer herstellung und diese enthaltende arzneimittel
WO1996014841A1 (en)	1996-05-23	Antiviral and antitumor pharmaceutical compositions
MXPA97000929A (en)	1998-01-01	Use and useful compositions in the prophylaxis and therapy of conditions related to endotox
Horlick	1953	The serum lipids in atherosclerosis.